Ensysce Biosciences
LA JOLLA, CA · Biotechnology, Healthcare · 12 employees
Ensysce Biosciences, Inc. (NASDAQ: ENSC) is a clinical-stage biotech company developing a new class of prescription drugs that will provide patients and prescribers safer options for the use of potent prescription drugs, reducing abuse and preventing overdoses.
Funding history
- Series seed — $2.2M — Apr 2025
- Series seed — $1.1M — Apr 2025
- Funding Round — $5.1M — Sep 2024
- Series seed — $4.7M — Feb 2024
- Series seed — $2.8M — Mar 2023
Recent signals
- Nov 17, 2025: SEC 8-K (1.01): On November 13, 2025, Ensysce Biosciences, Inc. entered into a Securities Purchase Agreement with an institutional investor to conduct a registered direct offering. The agreement involves the issuance of 1,513 shares of Series B Preferred Stock and up to 665,922 shares of Common Stock, potentially generating gross proceeds of approximately $1.7 million before fees and expenses. The closing of this transaction took place on November 14, 2025, indicating a strategic move to bolster the company's capital structure. This agreement could significantly impact the company's funding capabilities moving forward.
- Apr 25, 2025: Raised $2.2M in Series seed
- Apr 14, 2025: Raised $1.1M in Series seed
- Sep 12, 2024: Raised $5.1M
- Feb 21, 2024: Raised $4.7M in Series seed
- Mar 01, 2023: Raised $2.8M in Series seed
- Aug 09, 2022: Raised $8.0M
- Jul 08, 2022: Raised $4.2M in Series seed
See plans & pricing → Track Ensysce Biosciences’s funding, hiring, and signals — with verified contacts — on Fundz.